{"schema_version":"secwatch.filing_event.v1","accession":"0001193125-26-133332","form_type":"8-K","ticker":"PVLA","cik":"0001583648","company_name":"PALVELLA THERAPEUTICS, INC.","filed_at":"2026-03-31T23:59:59+00:00","discovered_at":"2026-05-14T18:02:35.535684+00:00","generated_at":"2026-05-15T08:09:45.619316+00:00","sec_items":["2.02","7.01","9.01"],"event_type":"earnings","sentiment":"positive","materiality_score":0.85,"calibrated_materiality_score":0.85,"confidence":"high","headline":"Palvella reports FY2025 net loss $41.7M; Phase 3 SELVA success paves path to NDA in H2 2026","bullets":["Net loss $41.7M ($3.71 per share) vs $17.4M ($7.83) in FY2024; R&D $22.8M, G&A $15.8M.","Cash $58M at Dec 31; pro forma cash ~$274M after $230M oversubscribed equity offering closed Feb 2026.","Phase 3 SELVA for microcystic LMs met primary endpoint (p<0.001); NDA submission on track for H2 2026.","Phase 3 trial for cutaneous venous malformations planned H2 2026; Phase 2 for angiokeratomas in Q2 2026.","Company to announce fourth QTORIN rapamycin indication and third platform product in H2 2026."],"urls":{"canonical":"https://secwatch.observer/filing/0001193125-26-133332","json":"https://secwatch.observer/filing/0001193125-26-133332.json","markdown":"https://secwatch.observer/filing/0001193125-26-133332.md","text":"https://secwatch.observer/filing/0001193125-26-133332.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1583648/000119312526133332/0001193125-26-133332-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1583648/000119312526133332/pvla-20260331.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-15T08:09:45.619316+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"d5123a014271eebd123544d297e22fddb2372105","claim":"PALVELLA THERAPEUTICS, INC. reported financial results for full year ending December 31, 2025.","evidence_excerpt":"On March 31, 2026, Palvella Therapeutics, Inc. (the “ Company ”) announced its financial results for the year ended December 31, 2025. A copy of the press release is being furnished as Exhibit 99.1 to this Current Report on Form 8-K and is incorporated herein by reference.","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1583648/000119312526133332/0001193125-26-133332-index.htm","confidence":0.95,"family_label":"Earnings Releases","details":[{"label":"Period","value":"full year ending December 31, 2025"},{"label":"Result","value":"reported results"}],"fact_type":"earnings_release"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}